ERBB2 and breast cancer: Concerning molecular subtypes, the frequency of positive RANK expression was lowest among patients with luminal A-like breast cancer (19.5%), increasing in those with luminal B-like breast cancer (26.0%), HER2-positive breast cancer (55.2%), and TNBC (67.2%).